NORTHVALE, N.J., Nov. 28, 2017 /PRNewswire/ — ADM Tronics Unlimited, Inc. (OTCQB: ADMT), a technology-based developer and manufacturer of innovative technologies and products, today released the following investor update.
In 2013 ADMT management remodeled the company’s business plan, focusing on its core competency in medical device services for the design, development, regulatory and manufacturing of medical devices for clients.
As a result of this strategy, ADMT reported profits in 17 of its last 18 quarters. These earnings have kept the company in a strong financial position, eliminated debt and enabled ADMT to deploy resources to develop its own proprietary medical technologies. This was accomplished without having to raise capital from outside sources. Management believes the company is now positioned for another strategic move, which can result in an enduring period of impressive growth.
ADMT now has a series of “brand name” proprietary medical technologies which the Company intends to bring to market over the next 12 months. These include:
– Tinnitus Shield™, a patent-pending hearing technology to protect against damaging sounds shown to have caused tinnitus, a debilitating condition of chronic ringing in the ears;
– Aurex-3®, a patented, non-invasive therapy device for millions of people already afflicted with tinnitus, prevalent in the military, music industry and other occupations exposed to damaging sound levels;
– Alvio™, a respiratory platform technology targeted for use in respiratory training applications, for use by athletes and others, and for medical respiratory indications such as COPD, asthma as well as for deployment in hospitals for post-surgical respiratory therapy;
– Sonotron®, a non-invasive therapy technology for the treatment of pain associated with inflammatory joint conditions such as osteoarthritis, tendinitis, bursitis, and epicondylitis, many of which currently treated with opioids.
These technologies address large markets in the US and internationally, each ranging from $100 million to over $1 billion. Alvio, Aurex-3 and Sonotron will be submitted to the FDA seeking clearance to market in the US, and to regulatory authorities for international distribution. All three technologies will incorporate state-of-the-art digital control, allowing for smartphone, tablet and cloud connectivity between patient and healthcare providers, which can significantly improve patient usability and compliance.
Andre’ DiMino, President and CEO of ADMT stated, “We have received strong interest from potential distribution partners for the distribution and sale of our new medical device technologies. We anticipate the launch of Tinnitus Shield in the near future and Alvio, Aurex-3 and Sonotron